Clinical Trial Update: A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered Revusiran (ALN-TTRSC) in he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Drugs mentioned

• Revusiran (ALN-TTRSC)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis | Phase 1 | Status: COMPLETED